XBIvsXPHETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) and State Street SPDR S&P Pharmaceuticals ETF (XPH) belong to the same industry segment: US Health Care. XBI's top 2 sector exposures are Healthcare and Finance. In contrast, XPH's top sector exposures are Healthcare. Both XBI and XPH have the same Total Expense Ratio (TER) of 0.35%. XBI is up 22.77% year-to-date (YTD) with +$853M in YTD flows. XPH performs worse with 12.1% YTD performance, and +$186M in YTD flows. Run a side-by-side ETF comparison of XBI and XPH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs XPH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/23/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI XPH | -3.93%-5.42% | -1.72%-8.29% | +22.77%+12.10% | +39.61%+29.83% | +130.21%+79.04% | +20.98%+38.62% |
| Flows | XBI XPH | +$229M-$80M | +$343M+$14M | +$853M+$186M | +$1.24B+$206M | +$276M+$160M | +$1.96B+$157M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI XPH | +30.32%+22.68% | +29.02%+23.32% | +28.46%+20.82% | +33.06%+21.10% |
| Max drawdown | XBI XPH | -14.89%-16.58% | -14.89%-16.58% | -32.94%-23.45% | -53.28%-30.87% |
| Max drawdown duration | XBI XPH | 65d65d | 65d65d | 331d322d | 1622d1452d |
Trading data
XBI | XPH | |
Last sale 10/26/2026 at 1:30 PM | $150.51 | $62.94 |
| Previous close 10/23/2026 | $149.54 | $62.70 |
| Consolidated volume 10/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XBI | XPH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/26/2026 at 1:30 PM
Live
Closed
XBI | XPH | |
|---|---|---|
| Last price | $150.51 | $62.94 |
| 1D performance | +0.65% | +0.37% |
| AuM | $10.36 B | $438.96 M |
| E/R | 0.35% | 0.35% |
Characteristics
XBI | XPH | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | State Street Investment Management |
| Benchmark | S&P Biotechnology Select Industry Index | S&P Pharmaceuticals Select Industry Index |
| N° of holdings | 149 | 62 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | June 19, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.53%
Other
4.47%
XPH
USA
89.77%
Other
10.23%
Sectors
XBI
Healthcare
99.18%
Other
0.82%
XPH
Healthcare
93.27%
Other
6.73%
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
21.91%
XPH
Total weight of top 15 holdings out of 15
34.13%
Top 15 holdings
Data as of August 31, 2026
XBI
Moderna, Inc.
2.81%
Twist Bioscience Corp.
1.89%
Apogee Therapeutics, Inc.
1.50%
Kymera Therapeutics, Inc.
1.40%
Halozyme Therapeutics, Inc.
1.39%
Natera, Inc.
1.37%
Praxis Precision Medicines, Inc.
1.34%
Oruka Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.31%
Travere Therapeutics, Inc.
1.30%
Protagonist Therapeutics, Inc.
1.28%
Dianthus Therapeutics, Inc.
1.27%
CG Oncology, Inc.
1.26%
Vaxcyte, Inc.
1.23%
Erasca, Inc.
1.23%
XPH
Amylyx Pharmaceuticals, Inc.
3.65%
Crinetics Pharmaceuticals, Inc.
3.60%
MBX Biosciences, Inc.
2.89%
Omeros Corp.
2.68%
Enliven Therapeutics, Inc.
2.28%
Nuvation Bio, Inc.
2.12%
Corcept Therapeutics, Inc.
2.11%
Eton Pharmaceuticals, Inc.
2.08%
Perrigo Co. Plc
1.91%
Edgewise Therapeutics, Inc.
1.85%
Nektar Therapeutics
1.83%
Merck & Co., Inc.
1.81%
Trevi Therapeutics, Inc.
1.80%
Tarsus Pharmaceuticals, Inc.
1.76%
Bristol Myers Squibb Co.
1.75%
Frequently asked questions about XBI and XPH
How have the XBI and XPH ETFs performed in 2026?
As of October 23, 2026, XBI is up 22.77% year-to-date (YTD), while XPH has returned 12.1%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or XPH?
Year-to-date, the XBI ETF saw +$853M in flows, compared to +$186M for XPH.
Which ETF is more volatile: XBI or XPH?
Over the past year, XBI had a volatility of 29.02%, while XPH experienced 23.32%.
Which ETF is bigger: XBI or XPH?
As of October 23, 2026, XBI holds $10.36 B in assets under management (AUM), while XPH manages $438.96 M.
What sectors do the XBI and XPH ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, XPH focuses on Healthcare.
What are the top holdings of the XBI ETF and XPH ETF?
XBI top holdings include Moderna, Inc., Twist Bioscience Corp. and Apogee Therapeutics, Inc.. XPH holds in its top three: Amylyx Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc. and MBX Biosciences, Inc..
Which ETF is more diversified: XBI or XPH?
XBI holds 152 securities with 21.91% of its assets in the top 15. XPH has 62 securities and a top 15 weight of 34.13%.
Advertisement
Latest news about XBI & XPH
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Advertisement
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
